Data from Pharmawand - Curated by Toby Galbraith - Date added 12 August 2017
Regeneron has announced that it will allow one of its key partnerships with the French drug maker Sanofi to terminate at the end of the year without an extension. The companies’ Antibody Discovery Agreement was responsible for the discovery and development of such drugs as alirocumab (Praluent), dupilumab (Dupixent), and sarilumab (Kevzara), as well as the proposed monoclonal antibodies REGN 2810, REGN 3500, and REGN 3767. Sanofi and Regneron will continue to co-develop REGN 2810, a programmed death-1 antibody, and REGN 3767, a lymphocyte activation gene-3 antibody (both for the treatment of cancer) under their immuno-oncology collaboration. That separate agreement will remain in force through at least 2020. The joint development and eventual prospective commercialization of REGN 3500, an IL-33 antibody for the treatment of inflammatory diseases, will continue as part of their Antibody License and Collaboration Agreement. Regeneron also reports that it has entered into clinical study agreements for RGN 2810 with Inovo Pharmaceuticals and SillaJen to evaluate the proposed antibody for use in combination with their own product candidates. Regeneron indicated that it retained the right to develop products initiated under the Antibody Discovery Agreement, either alone or in conjunction with other companies, after the Sanofi agreement lapses.